VolitionRx Announces Data Showing the Prognostic Value of its Nu.Q® Cancer Test

Data ReadoutpositiveNu.Q® Cancer AssayPositive

AI Analysis

Summary

VolitionRx announced clinical study data showing the prognostic value of its Nu.Q® Cancer Assay in newly diagnosed lung cancer patients. The company is promoting its epigenetics-based diagnostic test for oncology applications.

Outcome Details

Clinical study demonstrates significant prognostic value of Nu.Q® Cancer Assay in newly diagnosed lung cancer

Importance:5/10

Sentiment:

0.60

oncologydiagnosticsepigeneticsprognosticlung cancer

Related Companies

$VNRX

Read the original article

Published by PR Newswire Biotech on July 7, 2026 12:17 PM

Read Original